Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia .
Addex TherapeuticsJune 29, 2021 GMT
Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5, or mGlu5 to downregulate this neurotransmission through allosteric modulation.
Message :
Required fields Geneva, Switzerland, May 24, 2021 Addex Th
https://www.globenewswire.com/Tracker?data=GKEDSALQ3NE4EtVCK9RzLXOk8Q1WB4CkSAscPRzRqf0SdKsQfRwX9gF3D5OianoM6yqhedJ0aWDLbl85uBW8pGIBsUsozfgyWuKSHEalz5Y=
e
https://www.globenewswire.com/Tracker?data= w0gykO1cRWXvNInzg 3desjb1 u59TFS0A9iWd0zSqOojFGKcGUUTA-pVC88i-7tgLyk1ZFhlOA qCsbfnT9w==
rapeutics
https://www.globenewswire.com/Tracker?data=Hs rkfRwMjZ7W-Q8M7njxKHxgbDMLkKODX R98HbsH48L3DiAk0zV907yb2MqLBez4xLV5rL mMX9NC-yZhLsWbD6D6sL4p11kl1LT-ApNA=
(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company
pioneering allosteric modulation-based drug discovery and development,
announced today that Tim Dyer, Chief Executive Officer, will participate
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Increases Issued Share Capital to Create Treasury Shares
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its share capital from 39,748,635 to 49,272,952 through the issue of 9,524,317 new registered shares at a nominal value of CHF1 each to Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company’s authorized capital, are listed on the SIX Swiss Exchange. The transaction has been executed to provide the Group with additional future financing flexibility.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex to Participate at the 4ᵗʰ Annual Neuroscience Innovation Forum
Addex TherapeuticsApril 26, 2021 GMT
Geneva, Switzerland, April 26, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, will present at the 4ᵗʰ Annual Neuroscience Innovation Forum (April 26 - 30, 2021).
In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing to registered participants at the forum. Mr Dyer will also be speaking at the Parkinson’s & Movement Disorders Panel scheduled for 13:20 EDT, April 28, 2021.